(GEHC) GE HealthCare Technologies - Overview
Stock: Imaging, Ultrasound, Monitoring, Contrast, Radiopharmaceuticals
| Risk 5d forecast | |
|---|---|
| Volatility | 28.8% |
| Relative Tail Risk | -8.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -26.08 |
| Character TTM | |
|---|---|
| Beta | 1.281 |
| Beta Downside | 1.616 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.35% |
| CAGR/Max DD | 0.10 |
EPS (Earnings per Share)
Revenue
Description: GEHC GE HealthCare Technologies February 11, 2026
GE HealthCare Technologies Inc. (NASDAQ: GEHC) develops, manufactures, and markets diagnostic and therapeutic products plus digital solutions across four operating segments: Imaging (e.g., CT, MR, X-ray, molecular imaging), Advanced Visualization Solutions (ultrasound, interventional and surgical guidance), Patient Care Solutions (monitoring, cardiology, anesthesia, consumables), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals). The firm serves U.S., Canadian, and international markets, leveraging an integrated hardware-software-services model to capture revenue throughout the patient-care continuum.
Key recent metrics (FY 2024, disclosed Feb 2025): total revenue $22.5 billion (+5.2% YoY), imaging segment contributing 58% of sales, and operating margin expanding to 12.8% after a 150 bp improvement in cost-of-goods-sold efficiency. R&D spend reached $1.9 billion (≈8.4% of revenue), reflecting accelerated investment in AI-enhanced imaging and cloud-based analytics. The global medical imaging market is projected to grow ~6% CAGR through 2030, driven by an aging population, increasing outpatient imaging volumes, and adoption of AI-assisted diagnostics-factors that align with GEHC’s strategic focus.
For a deeper quantitative dive, you might explore ValueRay’s detailed valuation models for GEHC.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 1.68b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.60 > 1.0 |
| NWC/Revenue: 8.14% < 20% (prev -0.19%; Δ 8.33% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.99b > Net Income 1.68b |
| Net Debt (5.49b) to EBITDA (3.58b): 1.53 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (460.3m) vs 12m ago 0.28% < -2% |
| Gross Margin: 43.49% > 18% (prev 0.42%; Δ 4308 % > 0.5%) |
| Asset Turnover: 56.00% > 50% (prev 59.45%; Δ -3.44% > 0%) |
| Interest Coverage Ratio: 5.78 > 6 (EBITDA TTM 3.58b / Interest Expense TTM 450.0m) |
Altman Z'' 1.40
| A: 0.04 (Total Current Assets 10.70b - Total Current Liabilities 9.11b) / Total Assets 36.91b |
| B: 0.14 (Retained Earnings 5.28b / Total Assets 36.91b) |
| C: 0.07 (EBIT TTM 2.60b / Avg Total Assets 35.00b) |
| D: 0.15 (Book Value of Equity 3.90b / Total Liabilities 26.31b) |
| Altman-Z'' Score: 1.40 = BB |
Beneish M -3.16
| DSRI: 0.91 (Receivables 3.96b/4.38b, Revenue 19.60b/19.67b) |
| GMI: 0.96 (GM 43.49% / 41.70%) |
| AQI: 0.99 (AQ_t 0.63 / AQ_t-1 0.64) |
| SGI: 1.00 (Revenue 19.60b / 19.67b) |
| TATA: -0.01 (NI 1.68b - CFO 1.99b) / TA 36.91b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of GEHC shares?
Over the past week, the price has changed by -4.45%, over one month by -9.49%, over three months by +4.94% and over the past year by -8.27%.
Is GEHC a buy, sell or hold?
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GEHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.3 | 18.6% |
| Analysts Target Price | 93.3 | 18.6% |
| ValueRay Target Price | 78.8 | 0.2% |
GEHC Fundamental Data Overview February 11, 2026
P/E Forward = 17.0068
P/S = 1.7474
P/B = 3.5414
P/EG = 2.2551
Revenue TTM = 19.60b USD
EBIT TTM = 2.60b USD
EBITDA TTM = 3.58b USD
Long Term Debt = 9.49b USD (from longTermDebt, last quarter)
Short Term Debt = 508.0m USD (from shortTermDebt, last quarter)
Debt = 10.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.49b USD (from netDebt column, last quarter)
Enterprise Value = 41.53b USD (36.04b + Debt 10.00b - CCE 4.51b)
Interest Coverage Ratio = 5.78 (Ebit TTM 2.60b / Interest Expense TTM 450.0m)
EV/FCF = 27.58x (Enterprise Value 41.53b / FCF TTM 1.51b)
FCF Yield = 3.63% (FCF TTM 1.51b / Enterprise Value 41.53b)
FCF Margin = 7.68% (FCF TTM 1.51b / Revenue TTM 19.60b)
Net Margin = 8.57% (Net Income TTM 1.68b / Revenue TTM 19.60b)
Gross Margin = 43.49% ((Revenue TTM 19.60b - Cost of Revenue TTM 11.07b) / Revenue TTM)
Gross Margin QoQ = 54.34% (prev 38.69%)
Tobins Q-Ratio = 1.13 (Enterprise Value 41.53b / Total Assets 36.91b)
Interest Expense / Debt = 1.03% (Interest Expense 103.0m / Debt 10.00b)
Taxrate = 26.73% (54.0m / 202.0m)
NOPAT = 1.90b (EBIT 2.60b * (1 - 26.73%))
Current Ratio = 1.18 (Total Current Assets 10.70b / Total Current Liabilities 9.11b)
Debt / Equity = 0.96 (Debt 10.00b / totalStockholderEquity, last quarter 10.38b)
Debt / EBITDA = 1.53 (Net Debt 5.49b / EBITDA 3.58b)
Debt / FCF = 3.65 (Net Debt 5.49b / FCF TTM 1.51b)
Total Stockholder Equity = 9.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.80% (Net Income 1.68b / Total Assets 36.91b)
RoE = 17.11% (Net Income TTM 1.68b / Total Stockholder Equity 9.82b)
RoCE = 13.46% (EBIT 2.60b / Capital Employed (Equity 9.82b + L.T.Debt 9.49b))
RoIC = 9.70% (NOPAT 1.90b / Invested Capital 19.65b)
WACC = 8.48% (E(36.04b)/V(46.04b) * Re(10.63%) + D(10.00b)/V(46.04b) * Rd(1.03%) * (1-Tc(0.27)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.25%
[DCF Debug] Terminal Value 75.86% ; FCFF base≈1.52b ; Y1≈1.48b ; Y5≈1.47b
Fair Price DCF = 40.26 (EV 23.84b - Net Debt 5.49b = Equity 18.35b / Shares 455.7m; r=8.48% [WACC]; 5y FCF grow -4.08% → 2.90% )
EPS Correlation: -3.01 | EPS CAGR: -7.61% | SUE: 0.42 | # QB: 0
Revenue Correlation: 56.90 | Revenue CAGR: 1.98% | SUE: 1.11 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.06 | Chg30d=+0.066 | Revisions Net=+7 | Analysts=16
EPS current Year (2026-12-31): EPS=5.03 | Chg30d=+0.101 | Revisions Net=+15 | Growth EPS=+9.5% | Growth Revenue=+4.8%
EPS next Year (2027-12-31): EPS=5.57 | Chg30d=+0.052 | Revisions Net=+8 | Growth EPS=+10.8% | Growth Revenue=+4.6%